

Resource Summary Report

Generated by T1D on Aug 9, 2026

Olink Bioscience

RRID:SCR_003899

Type: Tool

Proper Citation

Olink Bioscience (RRID:SCR_003899)

Resource Information

URL: <http://www.olink.com/>

Proper Citation: Olink Bioscience (RRID:SCR_003899)

Description: Commercial organization that produces products for biomarker research and development. Their goal is to help customers and collaborators to improve clinical decisions through the use of molecular biomarkers. Their tools bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology.

Abbreviations: Olink

Resource Type: commercial organization

Keywords: biomarker, disease

Resource Name: Olink Bioscience

Resource ID: SCR_003899

Alternate IDs: nlx_158232

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260808T185809+0000

Ratings and Alerts

No rating or validation information has been found for Olink Bioscience.

No alerts have been found for Olink Bioscience.

Data and Source Information

Usage and Citation Metrics

We found 342 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Bentvelzen MLM, et al. (2026) Disentangling patient, disease, and treatment effects: proteomic and metabolomic differences in early versus established psoriatic arthritis. *Rheumatology advances in practice*, 10(1), rkaf136.

de Ligt LA, et al. (2026) Effect of Red Blood Cell Transfusion on Inflammatory and Angiogenic Pathways in Patients With Sickle Cell Disease. *American journal of hematology*, 101(4), 718.

Shi Y, et al. (2026) Blood-based biomarker discovery for early pregnancy loss using integrative multi-omics strategies. *EBioMedicine*, 127, 106253.

Murthy A, et al. (2026) Proteomic Profile After Intervention With Eplerenone Among Persons With HIV. *Open forum infectious diseases*, 13(4), ofag207.

Grauers Wiktorin H, et al. (2026) Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients. *Biomarker research*, 14(1).

Berge M, et al. (2026) Cytokines and immunologic checkpoint molecules in predicting success of allergen immunotherapy. *Scientific reports*, 16(1).

Delemarre EM, et al. (2026) Proteomic Signatures Over Age Reveal Significant Changes From Infancy Till Late Adulthood. *Advanced biology*, 10(1), e00455.

McFarlin BE, et al. (2026) Dulaglutide Effect on Proteins Associated With CKD Progression. *Kidney international reports*, 11(4), 103789.

Shao Y, et al. (2026) Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. *Signal transduction and targeted therapy*, 11(1).

Chen Y, et al. (2026) USP1-mediated lipophagy-lipogenesis axis drives cholangiocarcinoma progression and immune evasion. *Journal for immunotherapy of cancer*, 14(6).

Salib M, et al. (2026) Proteomic phenotyping with machine learning for cardiovascular outcomes in haemodialysis: insights from the AURORA trial. *European heart journal. Digital health*, 7(3), ztag044.

Zhang W, et al. (2026) Iparomlimab and tuvonralimab (QL1706) combined definitive chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma (QL1706-IIT-02): a single arm, phase 2 trial. *EClinicalMedicine*, 92, 103758.

Garcia-Peña A, et al. (2026) Serum proteomics mirrors the histopathological changes underlying different etiologies of primary mitral valve disease. *Bioscience reports*, 46(1).

Braun M, et al. (2026) Inflammatory protein profiles and shunt response in iNPH. *Fluids and barriers of the CNS*, 23(1), 5.

Wu X, et al. (2026) Integrative metabolomics and proteomics reveal early cardiovascular risk signatures in PCOS female offspring. *Journal of ovarian research*, 19(1), 72.

He L, et al. (2026) Macrophage Gs? promotes NLRP3 stability and its intervention attenuates abdominal aortic aneurysm in male mice. *Nature communications*, 17(1).

McLouth CJ, et al. (2026) Sex differences in proteomic response to ischemic stroke. *Biology of sex differences*, 17(1).

Blujdea ER, et al. (2026) Microglia protein profiles in CSF across Alzheimer's disease clinical stages. *Nature aging*, 6(3), 520.

Huo W, et al. (2026) PET-microplastics trigger endothelial glycocalyx loss via ER stress and ROS unleashing IL-1?-driven SMC switching and early aortic structural impairment. *Journal of nanobiotechnology*, 24(1).

Wang Y, et al. (2026) OLINK proteomics identifies inflammatory protein signatures associated with vascular cognitive impairment in diabetes. *Frontiers in immunology*, 17, 1677578.